Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08VVR
|
|||
| Former ID |
DIB011936
|
|||
| Drug Name |
TY-51924
|
|||
| Indication | Myocardial infarction [ICD-11: BA41-BA43; ICD-9: 410] | Phase 2 | [1] | |
| Company |
Toa Eiyo KK
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C14H19N4NaO5S
|
|||
| Canonical SMILES |
CC1=C(C=C2CCCCC(C2=N1)COS(=O)(=O)O)C(=NC(=N)N)[O-].[Na+]
|
|||
| InChI |
1S/C14H20N4O5S.Na/c1-8-11(13(19)18-14(15)16)6-9-4-2-3-5-10(12(9)17-8)7-23-24(20,21)22;/h6,10H,2-5,7H2,1H3,(H,20,21,22)(H4,15,16,18,19);/q;+1/p-1
|
|||
| InChIKey |
ZLKLPVRVDNGUND-UHFFFAOYSA-M
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trial design and rationale of TY-51924 as a novel Na+/H+ exchanger inhibitor in patients with ST-elevation acute myocardial infarction undergoing percutaneous coronary intervention. J Cardiol. 2014 Jan;63(1):82-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.